Deciphering the Elevated Lipid via CD36 in Mantle Cell Lymphoma with Bortezomib Resistance Using Synchrotron-Based Fourier Transform Infrared Spectroscopy of Single Cells
Despite overall progress in improving cancer treatments, the complete response of mantle cell lymphoma (MCL) is still limited due to the inevitable development of drug resistance. More than half of patients did not attain response to bortezomib (BTZ), the approved treatment for relapsed or refractor...
Main Authors: | Sudjit Luanpitpong, Montira Janan, Kanjana Thumanu, Jirarat Poohadsuan, Napachai Rodboon, Phatchanat Klaihmon, Surapol Issaragrisil |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2019-04-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/11/4/576 |
Similar Items
-
Selective Cytotoxicity of Single and Dual Anti-CD19 and Anti-CD138 Chimeric Antigen Receptor-Natural Killer Cells against Hematologic Malignancies
by: Sudjit Luanpitpong, et al.
Published: (2021-01-01) -
Bortezomib-based therapy for transplant-ineligible East Asian patients with newly diagnosed mantle-cell lymphoma
by: Jin J, et al.
Published: (2018-07-01) -
Cyclin D1-CDK4 activity drives sensitivity to bortezomib in mantle cell lymphoma by blocking autophagy-mediated proteolysis of NOXA
by: Simon Heine, et al.
Published: (2018-09-01) -
Multi-center phase II trial of bortezomib and rituximab maintenance combination therapy in patients with mantle cell lymphoma after consolidative autologous stem cell transplantation
by: Robert W. Chen, et al.
Published: (2018-06-01) -
Synergistic suppression of the PI3K inhibitor CAL-101 with bortezomib on mantle cell lymphoma growth
by: Fu-Lian Qu, et al.
Published: (2015-12-01)